Hamlet BioPharma reports anti-tumor effects for Alpha1H

Hamlet BioPharma AB has announced the detection of significant anti-tumor effects in patients treated with its drug candidate Alpha1H. The company's statement indicated these effects were observed across a combination of clinical and molecular endpoints.

These findings suggest a potential role for Alpha1H in cancer treatment. The company is pursuing development programs for both oncology and infectious diseases.

Further details on the studies and future development plans are expected from the company, which has previously disclosed ongoing clinical trials, including a Phase III study for Alpha1H in bladder cancer.

Hamlet BioPharma AB is a Swedish biopharmaceutical company based in Lund, focused on developing new treatments for cancer and infections.